180 Wealth Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

180 Wealth Advisors’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-637	Closed	-$354K	–	373
2022 Q1	$354K	Sell	637 -118	-16%	-$71.1K	0.08%	245
2021 Q4	$442K	Buy	755 +134	+22%	+$100K	0.1%	197
2021 Q3	$448K	Buy	621 +7	+1%	+$5.24K	0.1%	205
2021 Q2	$469K	Buy	614 +106	+21%	+$64.5K	0.11%	186
2021 Q1	$302K	Buy	+508	New	+$301K	0.07%	247

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

180 Wealth Advisors's BIO Position: Q2 2022 in Review

180 Wealth Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2022, closing a stake of 637 shares — an estimated $354K sold.

180 Wealth Advisors first reported a position in BIO in Q1 2021 and held it in 5 quarters. The position peaked at $469K in Q2 2021. 500 funds tracked by Wall St. Rank hold BIO as of Q2 2022.

180 Wealth Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q2 2022 after selling out during the quarter.
180 Wealth Advisors sold 637 Bio-Rad Laboratories Class A shares in Q2 2022, an estimated $354K.
180 Wealth Advisors first reported a position in Bio-Rad Laboratories Class A in Q1 2021 and held it in 5 quarters.
180 Wealth Advisors's Bio-Rad Laboratories Class A position peaked at $469K in Q2 2021.
500 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2022.

Based on 180 Wealth Advisors's 13F filing for Q2 2022, filed 11 Jul 2022.